AAA dispute involving the breach of a contract between biopharmaceutical companies engaged in the development of monoclonal antibody therapeutics

IP litigation and damages

In an American Arbitration Association (AAA) dispute over early-stage drug candidates in a development agreement between two biopharmaceutical companies, CRA consultants quantified damages associated with the alleged breach of the agreement. Dr. Gregory K. Bell submitted an expert report quantifying actual loss damages and unjust enrichment and provided deposition and hearing testimony to support the damages assessment.

Meet our team

Additional Contributors